IP Library › Granted Patent US 12,252,544
Granted Patent B2
US 12,252,544 · App. 17/056,301 · Granted Mar 18, 2025

Anti-CD63 antibodies, conjugates, and uses thereof

Inventors: Katherine Cygnar (New York, NY); Andrew Baik (Bronx, NY); Christopher Schoenherr (Piermont, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/2896C12N9/2428A61K2039/505A61K48/00C07K2317/21C07K2317/31C07K2317/622C07K2317/77C07K2317/92C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,544
App. No.
17/056,301
Granted
Mar 18, 2025
Kind
B2
Abstract

Antibodies, portions, and fusion proteins thereof to CD63 are provided. Also provided are nucleic acid sequences encoding same. Also provided are compositions comprising and methods of using same, e.g., for treating a patient in need thereof.

Claims (26)

1. An anti-CD63 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) within the heavy chain variable region (HCVR) amino acid sequence and three light chain complementarity determining regions (LCDRs) within the light chain variable region (LCVR) amino acid sequence of an HCVR/LCVR pair selected from the group consisting of SEQ ID NOs: 2/10, SEQ ID NOs: 18/26, SEQ ID NOs: 34/42, SEQ ID NOs: 50/58, SEQ ID NOs: 66/74, SEQ ID NOs: 82/90, SEQ ID NOs: 98/106, SEQ ID NOs: 114/122, SEQ ID NOs: 130/138, SEQ ID NOs: 146/154, SEQ ID NOs: 162/170, SEQ ID NOs: 178/186, SEQ ID NOs: 194/202, SEQ ID NOs: 210/218, SEQ ID NOs: 226/234, SEQ ID NOs: 242/250, SEQ ID NOs: 258/266, SEQ ID NOs: 274/282, SEQ ID NOs: 290/282, SEQ ID NOs: 298/282, SEQ ID NOs: 306/282, SEQ ID NOs: 314/282, SEQ ID NOs: 322/282, and SEQ ID NOs: 330/282.

2. The anti-CD63 antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a set of six CDRs selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16, SEQ ID NOS: 20-22-24-28-30-32, SEQ ID NOs: 36-38-40-44-46-48, SEQ ID NOs: 52-54-56-60-62-64; SEQ ID NOs: 68-70-72-76-78-80; SEQ ID NOs: 84-86-88-92-94-96; SEQ ID NOs: 100-102-104-108-110-112; SEQ ID NOs: 116-118-120-124-126-128; SEQ ID NOs: 132-134-136-140-142-144; SEQ ID NOS: 148-150-152-156-158-160; SEQ ID NOs: 164-166-168-172-174-176; SEQ ID NOs: 180-182-184-188-190-192; SEQ ID NOs: 196-198-200-204-206-208; SEQ ID NOs: 212-214-216-220-222-224; SEQ ID NOs: 228-230-232-236-238-240; SEQ ID NOs: 244-246-248-252-254-256; SEQ ID NOs: 260-262-264-268-270-272; SEQ ID NOs: 276-278-280-284-286-288; SEQ ID NOs: 292-294-296-284-286-288; SEQ ID NOS: 300-302-304-284-286-288; SEQ ID NOs: 308-310-312-284-286-288; SEQ ID NOS: 316-318-320-284-286-288; SEQ ID NOs: 324-326-328-284-286-288, and SEQ ID NOs: 332-334-336-284-286-288.

3. The anti-CD63 antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, SEQ ID NOs: 18/26, SEQ ID NOs: 34/42, SEQ ID NOS: 50/58, SEQ ID NOs: 66/74, SEQ ID NOs: 82/90, SEQ ID NOs: 98/106, SEQ ID NOS: 114/122, SEQ ID NOs: 130/138, SEQ ID NOs: 146/154, SEQ ID NOs: 162/170, SEQ ID NOs: 178/186, SEQ ID NOs: 194/202, SEQ ID NOs: 210/218, SEQ ID NOs: 226/234, SEQ ID NOs: 242/250, SEQ ID NOs: 258/266, SEQ ID NOs: 274/282, SEQ ID NOS: 290/282, SEQ ID NOs: 298/282, SEQ ID NOs: 306/282, SEQ ID NOs: 314/282, SEQ ID NOs: 322/282, and SEQ ID NOs: 330/282.

4. A bispecific antigen-binding molecule comprising:

(i) a first antigen-binding domain comprising the anti-CD63 antibody or antigen-binding fragment thereof of claim 1 , and

(ii) a second antigen-binding domain that binds a target antigen.

5. The bispecific antigen-binding molecule of claim 4 , wherein the target antigen is a tumor associated antigen.

6. The bispecific antigen-binding molecule of claim 4 , wherein the first antigen-binding domain does not bind human cells that express CD63 but not the target antigen.

7. The bispecific antigen-binding molecule of claim 4 , wherein each of the first antigen-binding domain and the second antigen-binding domain is fully human.

8. The bispecific antigen-binding molecule of claim 4 , wherein the bispecific antigen-binding molecule binds both human CD63 and a human target antigen expressed on a cell and induces CD63 internalization and/or degradation of the human target antigen in that cell.

9. The bispecific antigen-binding molecule of claim 4 , wherein the bispecific antigen-binding molecule is not internalized by cells that express human CD63 but do not express the human target antigen.

10. The bispecific antigen-binding molecule of claim 4 , wherein the bispecific antigen-binding molecule is fully human.

11. The bispecific antigen-binding molecule of claim 4 , wherein the first antigen-binding domain binds human CD63 with a low binding affinity such that the bispecific antigen-binding molecule does not bind cells that express human CD63 alone but binds to cells that express both human CD63 and the target antigen.

12. A multidomain therapeutic protein comprising the anti-CD63 antibody or antigen-binding fragment thereof of claim 1 and an enzyme domain.

13. The multidomain therapeutic protein of claim 12 , wherein the enzyme domain comprises GAA, or a biologically active portion thereof.

14. The multidomain therapeutic protein of claim 12 , comprising an amino acid sequence set forth as SEQ ID NO: 364.

15. A polynucleotide comprising a sequence encoding the anti-CD63 antibody or antigen-binding fragment thereof of claim 1 .

16. A polynucleotide comprising a sequence encoding the multidomain therapeutic protein of claim 12 , wherein the polynucleotide is comprised within an AAV vector.

17. The polynucleotide of claim 16 , wherein the polynucleotide further comprises the sequences set forth as SEQ ID NO: 365 and SEQ ID NO: 366.

18. The polynucleotide of claim 17 , wherein the polynucleotide further comprises a liver specific enhancer and/or liver specific promoter.

19. The polynucleotide of claim 18 , wherein the liver specific enhancer comprises a sequence set forth as SEQ ID NO: 367 and/or the liver specific promoter comprises a sequence set forth as SEQ ID NO: 368.

20. A pharmaceutical composition comprising the anti-CD63 antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

21. A compound comprising the anti-CD63 antibody or antigen-binding fragment thereof of claim 1 for use in medicine.

22. The compound of claim 21 , for use in treating a CD63-associated disorder.

23. The compound of claim 22 , wherein the CD63-associated disorder is selected from the group consisting of mast cell (MC-) dependent diseases, rheumatoid arthritis, IgE-dependent allergic reactions and Fc-ER1-mediated allergic reaction, asthma, cancer and/or metastases.

24. The compound of claim 21 , for use in the identification and/or isolation of exosomes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2024
From: CYGNAR, KATHERINE; BAIK, ANDREW; SCHOENHERR, CHRISTOPHER; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 066778/0851 →
Continuity (4)
Provisional Application 62777592 · Dec 10, 2018
Provisional Application 62681563 · Jun 6, 2018
Provisional Application 62673098 · May 17, 2018
Related Publication 20210079109A1 · Mar 18, 2021
References Cited (400)
US 4444878A · Paulus · 1984 [cited by applicant]
US 4975278A · Senter et al. · 1990 [cited by applicant]
US 5030717A · Tramontano et al. · 1991 [cited by applicant]
US 5126258A · Lerner et al. · 1992 [cited by applicant]
US 5156965A · Schochetman et al. · 1992 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5229272A · Paul et al. · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5585108A · Ruddy et al. · 1996 [cited by applicant]
US 5601819A · Wong et al. · 1997 [cited by applicant]
US 5602021A · Davis et al. · 1997 [cited by applicant]
US 5714586A · Kunstmann et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5851527A · Hansen · 1998 [cited by applicant]
US 5858351A · Podsakoff et al. · 1999 [cited by applicant]
US 5962313A · Podsakoff et al. · 1999 [cited by applicant]
US 6235714B1 · Paul et al. · 2001 [cited by applicant]
US 6265389B1 · Burke · 2001 [cited by applicant]
US 6306393B1 · Goldenberg et al. · 2001 [cited by applicant]
US 6329503B1 · Afar et al. · 2001 [cited by applicant]
US 6335011B1 · Podsakoff et al. · 2002 [cited by applicant]
US 6372205B1 · Duncan et al. · 2002 [cited by applicant]
US 6387674B1 · Trasciatti et al. · 2002 [cited by applicant]
US 6479265B1 · Napper et al. · 2002 [cited by applicant]
US 6555525B2 · Burke · 2003 [cited by applicant]
US 6610290B2 · Podsakoff et al. · 2003 [cited by applicant]
US 6703488B1 · Burton et al. · 2004 [cited by applicant]
US 6855804B2 · Paul et al. · 2005 [cited by applicant]
US 7041298B2 · Deshaies et al. · 2006 [cited by applicant]
US 7105348B2 · Murphy et al. · 2006 [cited by applicant]
US 7223556B1 · Zhou et al. · 2007 [cited by applicant]
US 7235641B2 · Kufer et al. · 2007 [cited by applicant]
US 7335504B2 · Haupts et al. · 2008 [cited by applicant]
US 7371539B2 · Church et al. · 2008 [cited by applicant]
US 7431923B2 · Young et al. · 2008 [cited by applicant]
US 7442777B2 · Young et al. · 2008 [cited by applicant]
US 7560424B2 · LeBowitz et al. · 2009 [cited by applicant]
US 7704492B2 · Podsakoff et al. · 2010 [cited by applicant]
US 7750116B1 · Doronina et al. · 2010 [cited by applicant]
US 7754681B2 · Feng · 2010 [cited by applicant]
US 7771997B2 · Chen et al. · 2010 [cited by applicant]
US 7785856B2 · LeBowitz et al. · 2010 [cited by applicant]
US 7858367B2 · Amalfitano et al. · 2010 [cited by applicant]
US 7914787B2 · Goldenberg et al. · 2011 [cited by applicant]
US 8048991B2 · Lundgren-Åkerlund · 2011 [cited by applicant]
US 8058399B2 · Jung · 2011 [cited by applicant]
US 8257745B2 · Ketelson et al. · 2012 [cited by applicant]
US 8278036B2 · Kariko et al. · 2012 [cited by applicant]
US 8563255B2 · Lundgren-Åkerlund · 2013 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 8642835B2 · Macdonald et al. · 2014 [cited by applicant]
US 8679478B2 · Koeberl · 2014 [cited by applicant]
US 8785168B2 · LeBowitz et al. · 2014 [cited by applicant]
US 8815226B2 · Yurkovetskiy et al. · 2014 [cited by applicant]
US 9186420B2 · Koeberl · 2015 [cited by applicant]
US 9315790B2 · Sakuraba et al. · 2016 [cited by applicant]
US 9359437B2 · Davis et al. · 2016 [cited by applicant]
US 9453241B2 · Pan · 2016 [cited by applicant]
US 9545450B2 · Do · 2017 [cited by applicant]
US 9622459B2 · Macdonald et al. · 2017 [cited by applicant]
US 9738717B2 · Azorsa · 2017 [cited by applicant]
US 9849195B2 · Davidson · 2017 [cited by applicant]
US 9873868B2 · Koeberl et al. · 2018 [cited by applicant]
US 9950076B2 · Nittoli et al. · 2018 [cited by applicant]
US 10017581B2 · Armstrong et al. · 2018 [cited by applicant]
US 10087253B2 · Lundgren-Åkerlund · 2018 [cited by applicant]
US 10098905B2 · Koeberl · 2018 [cited by applicant]
US 10293000B2 · Rebar · 2019 [cited by applicant]
US 10512676B2 · Char et al. · 2019 [cited by applicant]
US 10556015B2 · Zhang et al. · 2020 [cited by applicant]
US 10759864B2 · Sonoda et al. · 2020 [cited by applicant]
US 10857212B2 · Do et al. · 2020 [cited by applicant]
US 10869906B2 · Kishnani et al. · 2020 [cited by applicant]
US 10912804B2 · Byrne et al. · 2021 [cited by applicant]
US 11129903B2 · Andreev et al. · 2021 [cited by applicant]
US 11191844B2 · Andreev et al. · 2021 [cited by applicant]
US 11208458B2 · Baik · 2021 [cited by examiner]
US 11352446B2 · Cygnar et al. · 2022 [cited by applicant]
US 11578135B2 · Papadopoulos et al. · 2023 [cited by applicant]
US 20030219415A1 · Podsakoff et al. · 2003 [cited by applicant]
US 20040204379A1 · Cheng et al. · 2004 [cited by applicant]
US 20040248262A1 · Koeberl et al. · 2004 [cited by applicant]
US 20040258666A1 · Passini et al. · 2004 [cited by applicant]
US 20050142141A1 · Pardridge et al. · 2005 [cited by applicant]
US 20050220766A1 · Amalfitano et al. · 2005 [cited by applicant]
US 20050244400A1 · LeBowitz et al. · 2005 [cited by applicant]
US 20060078542A1 · Mah et al. · 2006 [cited by applicant]
US 20060099184A1 · Podsakoff et al. · 2006 [cited by applicant]
US 20060099205A1 · Adams et al. · 2006 [cited by applicant]
US 20060171926A1 · Passini et al. · 2006 [cited by applicant]
US 20060182745A1 · Kraft et al. · 2006 [cited by applicant]
US 20060210474A1 · Young et al. · 2006 [cited by applicant]
US 20070041978A1 · Hatiori et al. · 2007 [cited by applicant]
US 20070258987A1 · Francisco et al. · 2007 [cited by applicant]
US 20070280945A1 · Stevens et al. · 2007 [cited by applicant]
US 20080044408A1 · Young et al. · 2008 [cited by applicant]
US 20080069803A1 · Podsakoff et al. · 2008 [cited by applicant]
US 20080089891A1 · Hahn et al. · 2008 [cited by applicant]
US 20080269149A1 · Bowles et al. · 2008 [cited by applicant]
US 20080279945A1 · Mah et al. · 2008 [cited by applicant]
US 20080305497A1 · Kosmeder et al. · 2008 [cited by applicant]
US 20090117091A1 · LeBowitz et al. · 2009 [cited by applicant]
US 20090155262A1 · Young et al. · 2009 [cited by applicant]
US 20090191178A1 · Zankel et al. · 2009 [cited by applicant]
US 20100081796A1 · Brinkmann et al. · 2010 [cited by applicant]
US 20100129314A1 · Singh et al. · 2010 [cited by applicant]
US 20100183577A1 · Stern et al. · 2010 [cited by applicant]
US 20100221225A1 · Byrne et al. · 2010 [cited by applicant]
US 20100233173A1 · Wu et al. · 2010 [cited by applicant]
US 20100330034A1 · Bigler et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110184049A1 · Chuah et al. · 2011 [cited by applicant]
US 20110195454A1 · McWhirter et al. · 2011 [cited by applicant]
US 20110223147A1 · Lebowitz et al. · 2011 [cited by applicant]
US 20120034625A1 · Lundgren-Åkerlund · 2012 [cited by applicant]
US 20120093794A1 · LeBowitz et al. · 2012 [cited by applicant]
US 20120183502A1 · Meeker et al. · 2012 [cited by applicant]
US 20120228565A1 · Adams et al. · 2012 [cited by applicant]
US 20120265001A1 · Asmatulu et al. · 2012 [cited by applicant]
US 20120283503A1 · Ostrovska et al. · 2012 [cited by applicant]
US 20120322861A1 · Byrne et al. · 2012 [cited by applicant]
US 20130101546A1 · Yurkovetskiy et al. · 2013 [cited by applicant]
US 20130243775A1 · Papadopoulos et al. · 2013 [cited by applicant]
US 20130259833A1 · Pan · 2013 [cited by applicant]
US 20130267473A1 · Piens et al. · 2013 [cited by applicant]
US 20140099716A1 · Lundgren-Åkerlund · 2014 [cited by applicant]
US 20140186326A1 · Canfield et al. · 2014 [cited by applicant]
US 20140243504A1 · Davis et al. · 2014 [cited by applicant]
US 20140356366A1 · Cheong et al. · 2014 [cited by applicant]
US 20150056221A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150196671A1 · Byrne et al. · 2015 [cited by applicant]
US 20150322149A1 · Bohrmann et al. · 2015 [cited by applicant]
US 20160089451A1 · Armstrong · 2016 [cited by applicant]
US 20160108133A1 · Armstrong et al. · 2016 [cited by applicant]
US 20160115229A1 · Azorsa · 2016 [cited by applicant]
US 20160319023A1 · Lundgren-Åkerlund · 2016 [cited by applicant]
US 20160369297A1 · Byrne et al. · 2016 [cited by applicant]
US 20160375147A1 · Nittoli et al. · 2016 [cited by applicant]
US 20170007715A1 · Andreev et al. · 2017 [cited by applicant]
US 20170028002A1 · Byrne et al. · 2017 [cited by applicant]
US 20170151346A1 · Zhao · 2017 [cited by applicant]
US 20170189497A1 · Do et al. · 2017 [cited by applicant]
US 20170209591A1 · Nittoli et al. · 2017 [cited by applicant]
US 20180002433A1 · Zhang et al. · 2018 [cited by applicant]
US 20180028676A1 · Armstrong · 2018 [cited by applicant]
US 20180036388A1 · McIvor et al. · 2018 [cited by applicant]
US 20180125949A1 · LeBowitz et al. · 2018 [cited by applicant]
US 20180236105A1 · Davidson et al. · 2018 [cited by applicant]
US 20180251571A1 · Armstrong et al. · 2018 [cited by applicant]
US 20180264090A1 · McIvor et al. · 2018 [cited by applicant]
US 20180271956A1 · McIvor et al. · 2018 [cited by applicant]
US 20180355017A1 · Baik et al. · 2018 [cited by applicant]
US 20180371440A1 · Koeberl et al. · 2018 [cited by applicant]
US 20190000984A1 · Andreev et al. · 2019 [cited by applicant]
US 20190030059A1 · Koeberl · 2019 [cited by applicant]
US 20190112588A1 · Baik et al. · 2019 [cited by applicant]
US 20190224246A1 · Rebar · 2019 [cited by applicant]
US 20190241633A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190269797A1 · Davidson et al. · 2019 [cited by applicant]
US 20190309061A1 · Papadopoulos et al. · 2019 [cited by applicant]
US 20190390184A1 · Mingozzi et al. · 2019 [cited by applicant]
US 20190390225A1 · Mingozzi et al. · 2019 [cited by applicant]
US 20200009267A1 · Davidson et al. · 2020 [cited by applicant]
US 20200095338A1 · Cygnar et al. · 2020 [cited by applicant]
US 20200248205A1 · Kirn et al. · 2020 [cited by applicant]
US 20200317798A1 · Sonoda et al. · 2020 [cited by applicant]
US 20200399623A1 · Baik et al. · 2020 [cited by applicant]
US 20200407746A1 · Vandendriessche et al. · 2020 [cited by applicant]
US 20210038739A1 · Takahashi et al. · 2021 [cited by applicant]
US 20210040464A1 · Armstrong et al. · 2021 [cited by applicant]
US 20210040503A1 · Mingozzi et al. · 2021 [cited by applicant]
US 20220008548A1 · Andreev et al. · 2022 [cited by applicant]
US 20220195011A1 · Baik et al. · 2022 [cited by applicant]
US 20220267477A1 · Cygnar et al. · 2022 [cited by applicant]
US 20230220100A1 · Cygnar et al. · 2023 [cited by applicant]
US 20230338477A1 · Baik et al. · 2023 [cited by applicant]
CN 104160033A · 2014 [cited by applicant]
CN 109071658A · 2018 [cited by examiner]
EP 1716232B1 · 2010 [cited by applicant]
EP 1587923B1 · 2011 [cited by applicant]
EP 1879624B1 · 2011 [cited by applicant]
EP 1620133B1 · 2015 [cited by applicant]
EP 2475376B1 · 2016 [cited by applicant]
EP 2420256B1 · 2016 [cited by applicant]
EP 2279210B1 · 2017 [cited by applicant]
EP 2861263B1 · 2017 [cited by applicant]
EP 3315606A1 · 2018 [cited by applicant]
EP 2269658B1 · 2018 [cited by applicant]
EP 2687597B1 · 2018 [cited by applicant]
EP 3075386B1 · 2019 [cited by applicant]
EP 3292875B1 · 2020 [cited by applicant]
EP 2981551B1 · 2020 [cited by applicant]
EP 3272773B1 · 2020 [cited by applicant]
EP 3461905B1 · 2020 [cited by applicant]
KR 1020170010896 · 2017 [cited by applicant]
WO 1997005266A1 · 1997 [cited by applicant]
WO WO1998016254A1 · 1998 [cited by applicant]
WO 1999036437A1 · 1999 [cited by applicant]
WO 2001036005A2 · 2001 [cited by applicant]
WO WO2003057179A2 · 2003 [cited by applicant]
WO WO2004023973A2 · 2004 [cited by applicant]
WO WO2005077333A2 · 2005 [cited by applicant]
WO 2005089808A2 · 2005 [cited by applicant]
WO WO2006072166A1 · 2006 [cited by applicant]
WO WO2006108052A2 · 2006 [cited by applicant]
WO 2007024323A2 · 2007 [cited by applicant]
WO WO2007075270A1 · 2007 [cited by applicant]
WO 2008011710A1 · 2008 [cited by applicant]
WO 2008011711A1 · 2008 [cited by applicant]
WO 2008014404A2 · 2008 [cited by applicant]
WO WO2008022295A1 · 2008 [cited by applicant]
WO 2008122039A2 · 2008 [cited by applicant]
WO WO2008143354A1 · 2008 [cited by applicant]
WO 2009094561A1 · 2009 [cited by applicant]
WO 2010010324A1 · 2010 [cited by applicant]
WO 2010115552A1 · 2010 [cited by applicant]
WO 2010119119A1 · 2010 [cited by applicant]
WO 2011012316A2 · 2011 [cited by applicant]
WO 2011018611A1 · 2011 [cited by applicant]
WO 2011029823A1 · 2011 [cited by applicant]
WO 2011130598A1 · 2011 [cited by applicant]
WO 2011147986A1 · 2011 [cited by applicant]
WO 2012005982A2 · 2012 [cited by applicant]
WO 2012125987A2 · 2012 [cited by applicant]
WO 2012143379A1 · 2012 [cited by applicant]
WO 2012166559A1 · 2012 [cited by applicant]
WO 2013053872A1 · 2013 [cited by applicant]
WO 2013053873A1 · 2013 [cited by applicant]
WO 2013055990A1 · 2013 [cited by applicant]
WO 2013055993A1 · 2013 [cited by applicant]
WO 2013068874A1 · 2013 [cited by applicant]
WO 2013085925A1 · 2013 [cited by applicant]
WO 2013138400A1 · 2013 [cited by applicant]
WO 2014065661A1 · 2014 [cited by applicant]
WO WO2014085621A1 · 2014 [cited by applicant]
WO 2014130723A1 · 2014 [cited by applicant]
WO 2014145090A1 · 2014 [cited by applicant]
WO 2014182970A1 · 2014 [cited by applicant]
WO WO2014185908A2 · 2014 [cited by applicant]
WO WO2015026907A1 · 2015 [cited by applicant]
WO 2015031396A1 · 2015 [cited by applicant]
WO WO2016044947A1 · 2016 [cited by applicant]
WO WO2016065319A1 · 2016 [cited by applicant]
WO WO2016077840A2 · 2016 [cited by applicant]
WO WO2016085820A1 · 2016 [cited by applicant]
WO 2016160615A1 · 2016 [cited by applicant]
WO WO2016179257A2 · 2016 [cited by applicant]
WO 2017007796A1 · 2017 [cited by applicant]
WO 2017190079A1 · 2017 [cited by applicant]
WO WO2017100467A2 · 2017 [cited by applicant]
WO 2017134197A1 · 2017 [cited by applicant]
WO WO2006088503A1 · 2017 [cited by applicant]
WO WO2017131496A1 · 2017 [cited by applicant]
WO WO2017147414A1 · 2017 [cited by applicant]
WO WO2018031424A1 · 2018 [cited by applicant]
WO WO2018138322A1 · 2018 [cited by applicant]
WO WO2018213340A1 · 2018 [cited by applicant]
WO 2018226861A1 · 2018 [cited by applicant]
WO WO2019075417A1 · 2019 [cited by applicant]
WO WO2019153009A1 · 2019 [cited by applicant]
WO WO2019157224A1 · 2019 [cited by examiner]
WO WO2019197428A1 · 2019 [cited by applicant]
WO WO2019222411A1 · 2019 [cited by applicant]
WO WO2019222663A1 · 2019 [cited by applicant]
WO 2020023390A1 · 2020 [cited by applicant]
WO 2020041773A1 · 2020 [cited by applicant]
WO WO2020028841A1 · 2020 [cited by applicant]
WO 2020223362A1 · 2020 [cited by applicant]
WO WO2020102645A1 · 2020 [cited by applicant]
WO WO2020117898A1 · 2020 [cited by applicant]
WO 2020163480A1 · 2020 [cited by applicant]
WO 2021005176A1 · 2021 [cited by applicant]
Oksvold, et. al. Magnetic Bead-Based Isolation of Exosomes. In: Sioud, M. (eds) RNA Interference. Methods in Molecular Biology. 1218:465-481 (2015) (Year: 2015). [cited by examiner]
De Goeij et. al. J Exp Med 201(3):385-396. (2005) (Year: 2005). [cited by examiner]
Gershoni et al., Epitope Mapping, Biodrugs 2007; 21 (3): 145-156p. 146 section 1.1 (Year: 2007). [cited by examiner]
Blythe et al., Benchmarking B cell epitope prediction: Underperformance of existing methods, Protein Science (2005), 14:246-248 p. 246 (Year: 2005). [cited by examiner]
Schreiber et al., 3D-Epitope-Explorer (3DEX): Localization of Conformational Epitopes within Three-Dimensional Structures of Proteins, Wiley Interscience, 42-44:60596 (2005) (Year: 2005). [cited by examiner]
Davidson et. al. 143(1):13-20 (2014) (Year: 2014). [cited by examiner]
Agarwal et al., “A Pictet-Spengler ligation for protein chemical modification,” Proc. Natl. Acad. Sci., USA, 2013, 110:46-51. [cited by applicant]
Ahmad et al., “scFv Antibody: Principles and Clinical Application,” Clinical and Developmental Immunology, vol. 2012, article ID 980250, 15 pages. [cited by applicant]
Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol., 1997, 273:927-948. [cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool,” J. Mol. Biol., 1990, 215:403-410. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 1997, 25(17):3389-3402. [cited by applicant]
Andreev et al., “Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC),” Molecular targets and Cance… [cited by applicant]
Andreev et al., “Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs,” Mol. Cancer Ther., Apr. 2017, 16(4):681-693. [cited by applicant]
Angal et al. (1993) “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Molecular Immunology 30(1):105-108 Abstract Only. [cited by applicant]
Anzai et al., “c-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors,” Blood, 2002, 99(12):4413-4421, doi:10.1182/blood.V99.12.4413. [cited by applicant]
Arnold et al. “Metabolic Biotinylation Provides a Unique Platform for the Purification and Targeting of Multiple AAV Vector Serotypes,” Molecular Therapy, 2006, 14(1):97-106. [cited by applicant]
Arribas and Cutler, “Weibel-Palade Body Membrane Proteins Exhibit Differential Trafficking After Exocytosis in Endothelial Cells,” Traffic, 2000, 1:783-793. [cited by applicant]
Aurnhammer et al., “Universal Real-Time PCR for the Detection and Quantification of Adeno-Associated Virus Serotype 2-Derived Inverted Terminal Repeat Sequences,” Hum. Gene Ther. Methods, Part B, 2012, 23:18-28. [cited by applicant]
Azad et al., “A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts,” Oncotarget, 2016, 7(11):12344-12358. [cited by applicant]
Baik et al., “Next-generation antibody-guided enzyme replacement therapy in Pompe disease mice,” Molecular Genetics and Metabolism, 2018, 123(2):S21 Abstract Only. [cited by applicant]
Banerjee et al., “Targeted and armed oncolytic adenovirus via chemoselective modification,” Bioorganic and Medicinal Chemistry Letters, 2011, 21(17):4985-4988. [cited by applicant]
Bareford and Swaan, “Endocytic mechanisms for targeted drug delivery,” Advanced Drug Delivery Reviews, Elsevier, Amsterdam, NL, 2007, 59(8):748-758. [cited by applicant]
Bartlett et al., “Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors,” Journal of Virology, 2000, 74(6):2777-2785. [cited by applicant]
Barzel et al., “Promoterless gene targeting without nucleases ameliorates hemophilia B in mice,” Nature, 2015, 517(7534):360-364. [cited by applicant]
Battig et al., “Programmable Release of Multiple Protein Drugs from Aptamer-Functionalized Hydrogels via Nucleic Acid Hybridization,” J. Am. Chem. Society., 2012, 134:12410-12413. [cited by applicant]
Beatty, “Trafficking from CD63-positive late endocytic multivesicular bodies is essential for intracellular development of Chlamydia trachomatis,” Journal of Cell Science, 2006, 119(2):350-359. [cited by applicant]
Benedict et al., “Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay,” J Immunol Methods., 1997, 201(2):223-231. [cited by applicant]
Berditchevski et al., “Specific Association of CD63 with the VLA-3 and VLA-6 Integrins,” Journal of Biological Chemistry, 1995, 270(30):17784-17790. [cited by applicant]
Berditchevski et al., “Characterization of Novel Complexes on the Cell Surface between Integrins and Proteins with 4 Transmembrane Domains (TM4 proteins),” Molecular Biology of the Cell, 1996, 7:193-207. [cited by applicant]
Berditchevski et al., “A Novel Link between Integrins, Transmembrane-4 Superfamily Proteins (CD63 and CD81), and Phosphatidylinositol 4-Kinase,” Journal of Biological Chemistry, Jan. 1997, 272(5):2595-2598. [cited by applicant]
Berditchevski et al., “Generation of Monoclonal Antibodies to Integrin-associated Proteins,” Journal of Biological Chemistry, Nov. 1997, 272(46):29174-29180. [cited by applicant]
Berditchevski et al., “Expression of the Palmitoylation-deficient CD151 Weakens the Association of α3β1 Integrin with the Tetraspanin-enriched Microdomains and Affects Integrin-dependent Signaling,” Journal of Biologica… [cited by applicant]
Bian et al., “Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus,” Cancer Gene Ther., 2005, 12:295-303. [cited by applicant]
Bian et al., “In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein,” Int. J. Oncol., 2006, 29:1359-1369. [cited by applicant]
Blechacz and Russell, “Measles Virus as An Oncolytic Vector Platform,” Current Gene Therapy, 2008, 8:162-175. [cited by applicant]
Bode et al., “Antibody-Directed Fibrinolysis: An Antibody Specific for Both Fibrin and Tissue Plasminogen Activator,” Journal of Biological Chemistry, Jan. 1989, 264(2):944-948. [cited by applicant]
Boersma et al., “DARPins and other repeat protein scaffolds: advances in engineering and applications,” Curr. Opin. Biotechnol., 2011, 22:849-885. [cited by applicant]
Bonardi et al., “Delivery of Saporin to Human B-Cell Lymphoma Using Bispecific Antibody: Targeting via CD22 but not CD19, CD37, or Immunoglobulin Results in Efficient Killing,” Cancer Research, Jul. 1993, 53(13):3015-30… [cited by applicant]
Boustany, “Lysosomal storage diseases—the horizon expands,” Nat. Rev. Neurol., Oct. 2013, 9(10):583-598. [cited by applicant]
Brissinck et al., (1993) “Bispecific Antibodies in Lymphoma,” Intern. Rev. Immunol., 10(2-3):187-194. [cited by applicant]
Campadelli-Fiume et al., “Rethinking herpes simplex virus: the way to oncolytic agents,” Reviews in Medical Virology, 2011, 21:213-226. [cited by applicant]
Carrico et al., “Introducing genetically encoded aldehydes into proteins,” Nat. Chem. Biol., 2007, 3:321-322. [cited by applicant]
Catelas et al., “Controlled Release of Bioactive Transforming Growth Factor Beta-1 from Fibrin Gels In Vitro,” Tissue Engineering: Part C, 2008, 14(2):119-128. [cited by applicant]
Chadwick et al., “Modification of Retroviral Tropism by Display of IGF-I,” Journal of Molecular Biology, 1999, 285:485-494. [cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv Drug Deliv Rev., 2013, 65(10):1357-1369. [cited by applicant]
Chiba, “Molecular Mechanism in α-Glucosidase and Glucoamylase,” Biosci. Biotechnol. Biochem., 1997, 61(8):1233-1239. [cited by applicant]
Chuah et al., “Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates,” Mol. Ther., 2014, 22(9):1605-1613. [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc. Natl. Acad. Sci. (USA), 1998, 95:652-656. [cited by applicant]
Dalba et al., “Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors,” Current Gene Therapy, 2005, 5:655-667. [cited by applicant]
De Goeij et al., “Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63,” Mol. Cancer Ther., 2016, 15(11):2688-2697. [cited by applicant]
Derosa et al., “Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system,” Gene Therapy, 2016, 23:699-707. [cited by applicant]
Desnick and Schuchman, “Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges,” 13 Annu. Rev. Genomics Hum. Genet., 2012, 13:307-335. [cited by applicant]
Devay et al., “Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates,” Bioconjugate Chem., 2017, 28(4):1102-1114, DOI: 10.1021/acs.bioconjchem.7b00013. [cited by applicant]
Dimauro and Spiegel, “Progress and problems in muscle glycogenosis,” Acta Myologica, Oct. 2011, 30(2):96-102. [cited by applicant]
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nature Biotechnology, 2003, 21(7):778-784 and p. 941 Corrigendum. [cited by applicant]
Doyle et al., “CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin,” Blood, 2011, 118(15):4265-427. [cited by applicant]
Ducry and Stump, “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate Chem., 2010, 21:5-13. [cited by applicant]
Duffield et al., “The tetraspanin CD63 enhances the internalization of the H,K-ATPase β-subunit,” Proc. Nail. Acad. Sci. USA, Dec. 2003, 100(26):15560-15565. [cited by applicant]
Egea et al., “Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling,” PNAS, 2012, 109(6):E309-E316. [cited by applicant]
Ehring, “Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions,” Analytical Biochemistry, 1999, 267(2):252-259. [cited by applicant]
Einfeld, et al., “Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions,” J. Virol., 2001, 75(23):11284-11291. [cited by applicant]
Engen and Smith, “The Basics of Ion Chromatography,” Anal. Chem., 2001, 73:256A-265A. [cited by applicant]
Engering and Pieters, “Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells,” International Immunology, 2001, 13(2):127-134. [cited by applicant]
Erlwein et al., “Chimeric Ecotropic MLV Envelope Proteins that Carry EGF Receptor-Specific Ligands and the Pseudomonas Exotoxin A Translocation Domain to Target Gene Transfer to Human Cancer Cells,” Virology, 2002, 302:… [cited by applicant]
Ferland et al., “The effect of chloroquine on lysosomal prolactin receptors in rat liver,” Endocrinology, 1984, 115(5):1842-1849. [cited by applicant]
Flannery et al., “Palmitoylation-dependent association with CD63 targets the CA2+ sensor synaptotagmin VII to lysosomes,” J. Cell Biol., Nov. 2010, 191(3):599-613. [cited by applicant]
Galanis, “Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges,” Clinical Pharmacology and Therapeutics, 2010, 88(5):620-625. [cited by applicant]
Galmiche et al., “Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting,” Journal of General Virology, 1997, 78:3019-… [cited by applicant]
Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,” PNAS, 2002, 99(18):11854-11859. [cited by applicant]
Genty et al., “Endocytosis and degradation of prolactin and its receptor in Chinese hamster ovary cells stably transfected with prolactin receptor cDNA,” Mol. Cell Endocrinol., 1994, 99(2):221-228. [cited by applicant]
Geuijen et al. “Affinity ranking of antibodies using flow cytometry: Application in antibody phage display-based target discovery,” J Immunol Methods, 2005, 302(1-2):68-77. [cited by applicant]
Ghaderi et al., “Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation,” Biotechnol. Genet. Eng. Rev., 2012, 28:147-175. [cited by applicant]
Ghosh et al., “An Endocytosed TGN38 Chimeric Protein is Delivered to the TGN after Trafficking Through the Endocytic Recycling Compartment in CHO Cells,” J. Cell Bioi., Aug. 1998, 142(4):923-936. [cited by applicant]
Gigout et al., “Altering AAV Tropism with Mosaic Viral Capsids,” Molecular Therapy, 2005, 11(6):856-865. [cited by applicant]
Girod et al., “Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2,” Nature Medicine, 1999, 5(9):1052-1056. [cited by applicant]
Glasgow et al., “A Strategy for Adenovirus Vector Targeting with a Secreted Single Chain Antibody,” PLOS One, 2009, 4(12):e8355, 12 pages. [cited by applicant]
Gonnet et al., “Exhaustive Matching of the Entire Protein Sequence Database,” Science, 1992, 256: 1443-1445. [cited by applicant]
Grabow and Jaeger, “Loaded-up microsponges,” Nature Materials, 2012, 11:268-269. [cited by applicant]
Gray et al., “Production of recombinant adeno-associated viral vectors and use in vitro and in vivo administration”, Current Protocols in Neuroscience, 2011, Chapter: Unit 4.17, 36 pages, doi:10.1002/0471142301.ns0417s5… [cited by applicant]
Grifman et al., “Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids,” Molecular Therapy, 2001, 3(6):964-975. [cited by applicant]
Guse et al., “Oncolytic vaccinia virus for the treatment of cancer,” Expert Opinion on Biological Therapy, 2011, 11(5):595-608. [cited by applicant]
Haijema et al., “Switching Species Tropism: an Effective Way to Manipulate the Feline Coronavirus Genome,” J. Virol., 2003, 77(8):4528-4538. [cited by applicant]
Hakomori, “Glycosphingolipids in Cellular Interaction, Differentiation, and Oncogenesis,” Annual Review of Biochemistry, Jul. 1981, 50:733-764. [cited by applicant]
Hamblett et al., “Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate,” American Association for Cancer Research, Oct. 15, 2004, 10(20):7063-7070. [cited by applicant]
Hammond et al., “Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen,” Journal of Virology, 2001, 75(5):2087-2096. [cited by applicant]
Hemler, (2008) “Targeting of tetraspanin proteins—potential benefits and strategies,” Nat. Rev. Drug. Discov. 7(9):747-758, doi: 10.1038/nrd2659. [cited by applicant]
Hemminki et al., “Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule,” Cancer Res., 2001, 61: 6377-6381. [cited by applicant]
Henning et al., “Genetic Modification of Adenovirus 5 Tropism by a Novel Class of Ligands Based on a Three-Helix Bundle Scaffold Derived from Staphylococcal Protein A,” Human Gene Therapy, 2002, 13:1427-1439. [cited by applicant]
Hesselink et al., “Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II,” Biochim. Biophys. Acta., 2003, 1637(2):164-170. [cited by applicant]
Hirst et al., “Characterization of a Fourth Adaptor-related Protein Complex,” Molecular Biology of the Cell, 1999, 10:2787-2802. [cited by applicant]
Hofer et al., “An engineered selenocysteine defines a unique class of antibody derivatives,” Proc. Natl. Acad. Sci., USA, 2008, 105:12451-12456. [cited by applicant]
Hollander et al., “Selection of Reaction Additives Used in the Preparation of Monomeric Antibody-Calicheamicin Conjugates,” Bioconjugate Chem., 2008, 19:358-361. [cited by applicant]
Holliger et al., ““Diabodies”: Small bivalent and bispecific antibody fragments,” PNAS USA, 1993, 90:6444-6448. [cited by applicant]
Jarantow et al., “Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody,” J Biol Chem., Oct. 9, 2015, 290(41):24689-24704, doi: 10… [cited by applicant]
Jeger et al., “Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase,” Angew Chemie, Inter. Ed., 2010, 49:9995-9997. [cited by applicant]
Junghans et al., “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,” Cancer Res. 1990, 50:1495-1502. [cited by applicant]
Kabat et al., (1991) “Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptors for Antigen, T-Cell Surface Antigens, alpha2-Microglobulins, Major Hi… [cited by applicant]
Kidd et al., “Fibrin hydrogels for lentiviral gene delivery in vitro and in vivo,” Journal of Controlled Release, 2012, 157(1):80-85. [cited by applicant]
Kitani et al., “A Cell Surface Glycoprotein of Rat Basophilic Leukemia Cells Close to the High Affinity IgE Receptor (FcεRI),” Journal of Biological Chemistry, 1991, 266(3):1903-1909. [cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, 2012, 4:6 653-663 (12 pages). [cited by applicant]
Klimstra et al., “Targeting Sindbis virus-based vectors to Fc receptor-positive cell types,” Virology, 2005, 338:9-21. [cited by applicant]
Kobayashi et al., “The Tetraspanin CD63/lamp3 Cycles between Endocytic and Secretory Compartments in Human Endothelial Cells,” Molecular Biology, May 2000, 11:1829-1843. [cited by applicant]
Koeberl et al., “Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle,” Mol. Genet. Metab., 2011, 103(2):107-112. [cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” mAbs, 2012, 4(2):182-197. [cited by applicant]
Kraft et al., “Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo,” JEM, 2005, 201(3):385-396. [cited by applicant]
Kraft et al., “The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis,” J. Immunol, 2013, 191(6):2871-2878. [cited by applicant]
Kufer et al., “A revival of bispecific antibodies,” Trends Biotechnol., 2004, 22(5):238-244. [cited by applicant]
Langer, “New Methods of Drug Delivery,” Science, 1990, 249:1527-1533. [cited by applicant]
Latysheva et al., “Syntenin-1 Is a New Component of Tetraspanin-Enriched Microdomains: Mechanisms and Consequences of the Interaction of Syntenin-1 with CD63,” Molecular and Cellular Biology, Oct. 2006, 26(20):7707-7718. [cited by applicant]
Lee et al., “Impaired Retrograde Membrane Traffic Through Endosomes in a Mutant CHO Cell Defective in Phosphalidyl Serine Synthesis,” Genes to Cells, 2012, 17:728-736. [cited by applicant]
Lekishvili et al., “The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility,” Journal of Cell Science, 2008, 121(5):685-694, doi:10.1242/jcs.0… [cited by applicant]
Lieu et al., “The Golgin GCC88 Is Required for Efficient Retrograde Transport of Cargo from the Early Endosomes to the Trans-Golgi Network,” Mol. Bioi. Cell, Dec. 2007, 18:4979-4991. [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design & Selection, 2009, 22(3):159-1… [cited by applicant]
Maecker et al., “The tetraspanin superfamily: molecular facilitators,” FASEB J., May 1997, 11(6)428-442. [cited by applicant]
Maga et al., “Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice,” J. Biol. Chem., 2013, 288(3):1428-1438. [cited by applicant]
Mantegazza et al., “CD63 Tetraspanin Slows Down Cell Migration and Translocates to the Endosomal-Lysosomal—MIICs Route after Extracellular Stimuli in Human Immature Dendritic Cells,” Blood, Aug. 2004, 104(4):1183-1190. [cited by applicant]
Martin et al., “Modeling antibody hypervariable loops: A combined algorithm,” Proc. Natl. Acad. Sci. USA, 1989, 86:9268-9272. [cited by applicant]
Metzelaar et al., “CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells,” J. Biol. Chem., 1991, 266(5):3239-3245. [cited by applicant]
Mordenti et al., “Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins,” Pharmaceutical Research, 1991, 8:1351-1359. [cited by applicant]
Muenzer, “Early initiation of enzyme replacement therapy for the mucopolysaccharidoses,” Mol. Genet. Metab., Feb. 2014, 111(2):63-72. [cited by applicant]
Nakamura and Russell “Oncolytic measles viruses for cancer therapy,” Expert Opinion on Biological Therapy, 2004, 4(10):1685-1692. [cited by applicant]
Nakano et al., “Herpes Simplex Virus Targeting to the EGF Receptor by a gD-Specific Soluble Bridging Molecule,” Mol. Ther., Apr. 2005, 11(4):617-624. [cited by applicant]
Nicklin and Baker, “Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy,” Curr. Gene Ther., 2002, 2:273-293. [cited by applicant]
Nishibori et al., “The Protein CD63 Is in Platelet Dense Granules, Is Deficient in a Patient with Hermansky-Pudlak Syndrome, and Appears Identical to Granulophysin,” J. Clin. Invest., 1993, 91(4):1775-1782. [cited by applicant]
Nishida-Aoki et al., “Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis,” Molecular Therapy, 2017, 25(1):181-191. [cited by applicant]
Nishida-Aoki et al., “Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis,” Molecular Therapy, 2017, 25(1):181-191 Supplemental Information (16 pages). [cited by applicant]
Ohno et al., “Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A,” Nature Biotechnology, 1997, 15:763-767. [cited by applicant]